Ferumoxytol - AMAG Pharmaceuticals
Alternative Names: Feraheme; Ferrosoferric oxide; RiensoLatest Information Update: 05 Nov 2023
At a glance
- Originator AMAG Pharmaceuticals
- Class Antianaemics; Contrast media; Diagnostic agents; Ferric compounds; Ferrous compounds; Heavy metals; Minerals; Vascular disorder therapies
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Iron deficiency anaemia
- Phase II Peripheral arterial disorders
Most Recent Events
- 19 May 2022 The Committee for Medicinal Products for Human Use (CHMP) initiates evaluation of ferumoxytol for Iron deficiency anaemia in European Union
- 01 Apr 2022 AMAG Pharmaceuticals completes a phase III trial in Iron deficiency anaemia in USA (IV) (NCT03657433)
- 16 Nov 2020 AMAG Pharmaceuticals has been acquired by Covis Pharma